Compare Stocks: ALPN, NBIX, JAZZ, and RDY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALPN Alpine Immune Sciences	$64.97	$64.81	$8.33 ▼ $65.00	$4.46B	0.97	1.92 million shs	N/A
JAZZ Jazz Pharmaceuticals	$214.44 -0.7%	$231.16	$128.80 ▼ $266.38	$13.31B	0.37	800,019 shs	1.04 million shs
NBIX Neurocrine Biosciences	$145.35 -0.5%	$146.49	$122.14 ▼ $186.12	$14.79B	0.4	1.30 million shs	2.01 million shs
RDY Dr. Reddy's Laboratories	$14.14 -0.2%	$12.58	$11.36 ▼ $15.67	$11.81B	0.29	3.29 million shs	1.93 million shs

10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALPN Alpine Immune Sciences	0.00%	0.00%	0.00%	0.00%	0.00%
JAZZ Jazz Pharmaceuticals	-0.71%	+4.25%	-9.01%	-18.03%	+55.80%
NBIX Neurocrine Biosciences	-0.51%	-0.36%	+1.52%	-12.47%	+1.49%
RDY Dr. Reddy's Laboratories	-0.38%	+2.84%	+15.27%	+16.68%	+6.25%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALPN Alpine Immune Sciences	$64.97	$64.81	$8.33 ▼ $65.00	$4.46B	0.97	1.92 million shs	N/A
JAZZ Jazz Pharmaceuticals	$214.44 -0.7%	$231.16	$128.80 ▼ $266.38	$13.31B	0.37	800,019 shs	1.04 million shs
NBIX Neurocrine Biosciences	$145.35 -0.5%	$146.49	$122.14 ▼ $186.12	$14.79B	0.4	1.30 million shs	2.01 million shs
RDY Dr. Reddy's Laboratories	$14.14 -0.2%	$12.58	$11.36 ▼ $15.67	$11.81B	0.29	3.29 million shs	1.93 million shs

10 Stocks Powering The Next AI Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALPN Alpine Immune Sciences	0.00%	0.00%	0.00%	0.00%	0.00%
JAZZ Jazz Pharmaceuticals	-0.71%	+4.25%	-9.01%	-18.03%	+55.80%
NBIX Neurocrine Biosciences	-0.51%	-0.36%	+1.52%	-12.47%	+1.49%
RDY Dr. Reddy's Laboratories	-0.38%	+2.84%	+15.27%	+16.68%	+6.25%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALPN Alpine Immune Sciences	0.00	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	2.95	Moderate Buy	$292.05	36.19% Upside
NBIX Neurocrine Biosciences	2.88	Moderate Buy	$201.14	38.38% Upside
RDY Dr. Reddy's Laboratories	2.17	Hold	$492.90	3,386.84% Upside

Current Analyst Ratings Breakdown

Latest ALPN, NBIX, JAZZ, and RDY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/28/2026	JAZZ Jazz Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Buy (B-) ➝ Hold (C+)
10/28/2026	JAZZ Jazz Pharmaceuticals	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Boost Price Target	Overweight	$276.00 ➝ $300.00
10/26/2026	RDY Dr. Reddy's Laboratories	JPMorgan Chase & Co. Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Underweight ➝ Neutral
10/25/2026	RDY Dr. Reddy's Laboratories	Jefferies Financial Group Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Underperform ➝ Hold	$13.90
10/21/2026	RDY Dr. Reddy's Laboratories	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Hold (C-)
10/21/2026	JAZZ Jazz Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Overweight	$322.00 ➝ $314.00
10/16/2026	NBIX Neurocrine Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Buy	$204.00
10/14/2026	NBIX Neurocrine Biosciences	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Hold (C+) ➝ Buy (B-)
10/12/2026	RDY Dr. Reddy's Laboratories	BNP Paribas Exane Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Outperform	$14.80
10/12/2026	NBIX Neurocrine Biosciences	BMO Capital Markets Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Market Perform	$164.00 ➝ $150.00
10/8/2026	JAZZ Jazz Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Outperform	$299.00 ➝ $296.00

(Data available from 11/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALPN Alpine Immune Sciences	$56.52M	78.85	N/A	N/A	$4.85 per share	13.40
JAZZ Jazz Pharmaceuticals	$4.27B	3.26	$17.01 per share	12.61	$71.07 per share	3.02
NBIX Neurocrine Biosciences	$2.86B	5.17	$5.01 per share	29.03	$32.63 per share	4.45
RDY Dr. Reddy's Laboratories	$3.58B	3.30	$0.85 per share	16.70	$4.87 per share	2.90

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALPN Alpine Immune Sciences	-$32.18M	-$0.64	N/A	N/A	N/A	-65.17%	-14.86%	-11.82%	N/A
JAZZ Jazz Pharmaceuticals	-$356.15M	$14.50	8.88	9.85	0.41	20.45%	33.97%	13.02%	11/2/2026 (Estimated)
NBIX Neurocrine Biosciences	$478.60M	$6.82	20.10	15.66	0.64	20.91%	22.43%	15.64%	11/2/2026 (Estimated)
RDY Dr. Reddy's Laboratories	$456M	$0.37	38.21	24.37	2.95	8.56%	7.91%	5.29%	N/A

Latest ALPN, NBIX, JAZZ, and RDY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/2/2026	Q3 2026	JAZZ Jazz Pharmaceuticals	-$4.05	-$3.88	+$0.17	-$7.48	$1.21 billion	$1.24 billion
11/2/2026	Q3 2026	NBIX Neurocrine Biosciences	$1.91	$3.29	+$1.38	$1.96	$1.04 billion	$1.12 billion
10/24/2026	Q2 26/27	RDY Dr. Reddy's Laboratories	$0.0968	$0.12	+$0.0232	$0.12	$894.94 million	$903.89 million
8/3/2026	Q2 2026	JAZZ Jazz Pharmaceuticals	$6.18	$5.71	-$0.47	$2.78	$1.11 billion	$1.21 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALPN Alpine Immune Sciences	N/A	N/A	N/A	N/A	N/A
JAZZ Jazz Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
NBIX Neurocrine Biosciences	N/A	N/A	N/A	N/A	N/A
RDY Dr. Reddy's Laboratories	$0.06	0.43%	+6.96%	16.22%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALPN Alpine Immune Sciences	N/A	9.56	9.56
JAZZ Jazz Pharmaceuticals	0.69	1.78	1.58
NBIX Neurocrine Biosciences	N/A	1.87	1.75
RDY Dr. Reddy's Laboratories	0.03	1.93	1.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALPN Alpine Immune Sciences	75.17%
JAZZ Jazz Pharmaceuticals	89.14%
NBIX Neurocrine Biosciences	92.59%
RDY Dr. Reddy's Laboratories	3.85%

Insider Ownership

Company	Insider Ownership
ALPN Alpine Immune Sciences	42.30%
JAZZ Jazz Pharmaceuticals	4.10%
NBIX Neurocrine Biosciences	4.60%
RDY Dr. Reddy's Laboratories	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALPN Alpine Immune Sciences	142	68.60 million	39.58 million	No Data
JAZZ Jazz Pharmaceuticals	2,890	64.92 million	62.25 million	Optionable
NBIX Neurocrine Biosciences	2,000	101.65 million	96.97 million	Optionable
RDY Dr. Reddy's Laboratories	27,527	834.67 million	817.98 million	Optionable

ALPN, NBIX, JAZZ, and RDY Headlines

Recent News About These Companies

Dr. Reddy’s Laboratories Ltd (RDY): Stock Analysis and Investor Outlook Amidst Diverse Global Operations

November 2 at 5:41 PM | directorstalkinterviews.com

Critical Review: Neurocrine Biosciences (NASDAQ:NBIX) and Dr. Reddy's Laboratories (NYSE:RDY)

November 2 at 6:15 AM | americanbankingnews.com

Dr. Reddy's Laboratories Ltd (NYSE:RDY) Stock Has Average Price Target of $492.90 According to Brokerages

October 30, 2026 | americanbankingnews.com

Dr. Reddy's Laboratories (NYSE:RDY) Raised to "Neutral" at JPMorgan Chase & Co.

October 28, 2026 | americanbankingnews.com

Dr. Reddy's Laboratories (NYSE:RDY) Shares Climb 4.8% on Earnings Beat

October 28, 2026 | americanbankingnews.com

Analysts Offer Insights on Healthcare Companies: Dr Reddy’s Laboratories (RDY) and Genmab (GMAB)

October 27, 2026 | theglobeandmail.com

RDY Q2 Earnings & Revenues Miss Estimates as Lenalidomide Sales Fall

October 26, 2026 | zacks.com

Dr. Reddy's Laboratories (NYSE:RDY) Stock Jumps 4.8% After Strong Earnings

October 26, 2026 | marketbeat.com

JPMorgan Chase & Co. Upgrades Dr. Reddy's Laboratories (NYSE:RDY) to Neutral

October 26, 2026 | marketbeat.com

Dr. Reddy's Laboratories Ltd (NYSE:RDY) Stock Has Consensus Target Price of $492.90

October 25, 2026 | marketbeat.com

Jefferies Upgrades Dr. Reddy\'s Laboratories Ltd. (DRRD:IN) (RDY) to Hold

October 25, 2026 | streetinsider.com

Dr. Reddy's Laboratories: 3 Key Takeaways for Long-Term Investors

October 25, 2026 | fool.com

JPMorgan Upgrades Dr. Reddy\'s Laboratories (DRRD:IN) (RDY) to Neutral

October 25, 2026 | streetinsider.com

Dr. Reddy\'s Laboratories (DRRD:IN) (RDY) PT Lowered to INR1,730 at Nomura/Instinet

October 25, 2026 | streetinsider.com

Dr. Reddy's Laboratories Limited (RDY) Q2 2027 Earnings Call Transcript

October 23, 2026 | seekingalpha.com

Dr. Reddy’s outlines semaglutide relaunch in November 2026 and reiterates 6M-7M devices target

October 23, 2026 | seekingalpha.com

Dr. Reddy's (RDY) Q2 2027 Earnings Call Transcript

October 23, 2026 | finance.yahoo.com

Dr. Reddy's Laboratories Q2 Earnings Call Highlights

October 23, 2026 | marketbeat.com

Dr. Reddy's Laboratories (NYSE:RDY) Posts Quarterly Earnings Results, Beats Estimates By $0.03 EPS

October 23, 2026 | marketbeat.com

Dr. Reddy's Laboratories Limited 2027 Q2 - Results - Earnings Call Presentation

October 23, 2026 | seekingalpha.com

Dr. Reddy's Laboratories Profit Drops In Q2

October 23, 2026 | rttnews.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALPN, NBIX, JAZZ, and RDY Company Descriptions

Alpine Immune Sciences NASDAQ:ALPN

Alpine Immune Sciences, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of immunotherapies through protein engineering technologies for treating autoimmune and inflammatory diseases. The company's product pipeline includes Povetacicept, a dual B cell cytokine antagonist, which is in Phase 2 clinical trial for the treatment of multiple autoimmune and inflammatory diseases; and Acazicolcept, a dual inhibitor of the CD28 and ICOS T cell costimulatory pathways that is in preclinical trial for the treatment of systemic lupus erythematosus. It is also developing RUBY-3 that has completed Phase 1 clinical trial for the treatment of glomerulonephritis; and RUBY-4, which has completed Phase 1 clinical trial for the treatment of cytopenias. The company was incorporated in 2007 and is headquartered in Seattle, Washington.

Jazz Pharmaceuticals NASDAQ:JAZZ

$214.44 -1.54 (-0.71%)

Closing price 11/2/2026 04:00 PM Eastern

Extended Trading

$212.89 -1.55 (-0.72%)

As of 11/2/2026 07:43 PM Eastern

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia. It also develops Zanidatamab to treat HER2-expressing gastroesophageal adenocarcinoma (GEA), and patients with HER2-expressing metastatic GEA; Zepzelca for the treatment of patients with select relapsed/refractory solid tumors based on limited response in three solid tumor cohorts; JZP815, a pan-RAF kinase inhibitor that targets components of the mitogen-activated protein kinase; JZP898, a conditionally-activated interferon alpha molecule; Epidiolex to treat LGS, DS, and TSC; Suvecaltamide to treat parkinson's disease tremor; JZP150, a fatty acid amide hydrolase inhibitor program to treat post-traumatic stress disorder; and JZP441 to treat narcolepsy, IH, and other sleep disorders. The company has licensing and collaboration agreements with XL-protein GmbH to extend the plasma half-life of selected asparaginase product candidates; Redx Pharma plc for preclinical activities Ras/Raf/MAP kinase pathway program; and Autifony Therapeutics Limited on discovering and developing drug candidates targeting two different ion channel targets associated with neurological disorders. The company was incorporated in 2003 and is headquartered in Dublin, Ireland.

Neurocrine Biosciences NASDAQ:NBIX

$145.35 -0.75 (-0.51%)

Closing price 11/2/2026 04:00 PM Eastern

Extended Trading

$154.33 +8.98 (+6.18%)

As of 11/2/2026 07:59 PM Eastern

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

Dr. Reddy's Laboratories NYSE:RDY

$14.14 -0.03 (-0.24%)

Closing price 11/2/2026 03:59 PM Eastern

Extended Trading

$14.14 0.00 (-0.01%)

As of 11/2/2026 07:38 PM Eastern

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALPN, NBIX, JAZZ, and RDY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALPN, NBIX, JAZZ, and RDY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALPN, NBIX, JAZZ, and RDY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALPN, NBIX, JAZZ, and RDY Company Descriptions

Alpine Immune Sciences NASDAQ:ALPN

Jazz Pharmaceuticals NASDAQ:JAZZ

Neurocrine Biosciences NASDAQ:NBIX

Dr. Reddy's Laboratories NYSE:RDY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ALPN, NBIX, JAZZ, and RDY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ALPN, NBIX, JAZZ, and RDY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ALPN, NBIX, JAZZ, and RDY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALPN, NBIX, JAZZ, and RDY Company Descriptions

Alpine Immune Sciences NASDAQ:ALPN

Jazz Pharmaceuticals NASDAQ:JAZZ

Neurocrine Biosciences NASDAQ:NBIX

Dr. Reddy's Laboratories NYSE:RDY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools